Human papillomavirus vaccine TA-HPV - Xenova

Drug Profile

Human papillomavirus vaccine TA-HPV - Xenova

Alternative Names: TA-HPV

Latest Information Update: 14 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Developer Xenova Group
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Vulvar intraepithelial neoplasia

Most Recent Events

  • 29 Jul 2004 Suspended - Phase-II for Anal intraepithelial neoplasia in United Kingdom (Intradermal)
  • 29 Jul 2004 Suspended - Phase-II for Cervical cancer in European Union (Intradermal)
  • 29 Jul 2004 Suspended - Phase-II for Cervical cancer in United Kingdom (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top